Trends in the treatment of metastatic colon and rectal cancer in elderly patients

Medical Care

Volumn 54, Issue 5, 2016, Pages 490-497

  Bradley, Cathy J ^a   Yabroff, K Robin ^b   Warren, Joan L ^b   Zeruto, Christopher ^c   Chawla, Neetu ^b   Lamont, Elizabeth B ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antineoplastic agents; Chemotherapy use; Colorectal cancer; Survival; Treatment costs

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOUROPYRIMIDINE; FLUOROURACIL; HEMOPOIETIC GROWTH FACTOR; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; DRUG COST; FEMALE; GERIATRIC PATIENT; HEALTH CARE COST; HOSPICE CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTATIC COLORECTAL CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; VERY ELDERLY; AGE; CANCER REGISTRY; COLONIC NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; METASTASIS; MORTALITY; PATHOLOGY; RECTAL NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MEDICARE; NEOPLASM METASTASIS; RECTAL NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84959082395     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000510     Document Type: Article

References (49)

1. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 1413-1418.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
3. Giusti RM, Shastri K, Pilaro AM, et al. US Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res. 2008; 14: 1296-1302.
4. Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomized phase 3 trial of panitumumab. Br J Cancer. 2007; 97: 1469-1474.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
6. Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol. 2012; 30: 3353-3360.
7. McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013; 31: 2600-2607.
8. Ryu A, Gibson T, McKellar M, et al. The slowdown in health care spending in 2009-11 reflected factors other than the weak economy and thus may persist. Health Aff (Millwood). 2013; 32: 835-840.
9. Beamesderfer A, Ranji U. US health care costs. 2012. Available at: http: //www.kaiseredu.org/Issue-Modules/US-Health-Care-Costs/Background-Brief.aspx. Accessed January. 25, 2016.
10. National Research Council. Delivering Affordable Cancer Care in the 21st Century: Workshop Summary. Washington, DC: The National Academies Press; 2013. Available at: http: //books.nap.edu/openbook. php?record-id=18273&page=3. Accessed January. 25, 2016.
11. National Cancer Institute. Seer stat fact sheets: colon and rectum. Available at: http: //seer.cancer.gov/statfacts/html/colorect.html. 2012. Accessed January. 25, 2016.
12. Venderbosch S, Doornebal J, Teerenstra S, et al. Outcome of the first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol. 2012; 51: 831-839.
13. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28: 4697-4705.
14. Saltz LB, Vox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343: 905-914.
15. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2, 691 patients in randomized controlled trials. J Clin Oncol. 2008; 26: 1443-1451.
16. Aparicio T, Desrame J, Lecomte T. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer. 2003; 89: 1439-1445.
17. Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012; 30: 608-615.
18. Hershman DL, Wright JD, Lim E, et al. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J Clin Oncol. 2013; 31: 3592-3599.
19. Lichtman SM. Call for changes in clinical trial reporting of older patients with cancer. J Clin Oncol. 2012; 30: 893-894.
20. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40(suppl): IV-55-61.
21. US Department of Health and Human Services, Center for Disease Control and Prevention. International classification of diseases, ninth revision, clinical modification. Vol. 1-3. 2012. Available at: http://online.statref.com.jproxy.lib.ecu.edu/document.aspx?FxId=110&Doc-ID=1&SessionID=1B8844AXNDVJKVMA. Accessed January. 25, 2016.
22. Swanson K. CPT Plus 2001: A Comprehensive Guide to Current Procedural Terminology. Los Angeles, CA: PMIC; 2001.
23. Abrams TA, Meyer G, Schrag D, et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2014; 106: 1-10.
24. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
25. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008; 100: 888-897.
26. Yabroff KR, Warren JL, Banthin J, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data sources?. Med Care. 2009; 47(suppl 1): S64-S69.
27. Centers for Medicare & Medicaid, Office of the Actuary. Alternative weighting of the hospital market basket input price index. 2008. Available at: https://www.cms.gov/Research-Statistics-Data-And-Systems/.Statistics-Trends-And-Reports/MedicareProgramRatesStats/Downloads/.alternativeindexweights.pdf. Accessed January. 25, 2016.
28. Centers for Medicare & Medicaid Services. Acute inpatient PPS. Available at: http: //www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html?redirect=/acuteinpatientpps/. 2012. Accessed January. 25, 2016.
29. Medpac. The construct of Medicare price indexes. 2002. Available at: http: //67.59.137.244/publications/congressional-reports/Mar02-AppA. pdf. Accessed January. 25, 2016.
30. Graubard B, Korn E. Analyzing health surveys for cancer-related objectives. J Natl Cancer Inst. 1999; 91: 1005-1016.
31. Thorpe K. Treated disease prevalence and spending per treated case drove most of the growth in health care spending in 1987-2009. Health Aff (Millwood). 2013; 32: 851-858.
32. Ferro S, Myer B, Wolff D, et al A variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care. 2008; 14: 717-725.
33. Food and Drug Administration. FDA alert: information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. 2007. Available at: http: //www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm126481.htm. Accessed January. 25, 2016.
34. Mullins C, Hsiao F, Onukwugha E, et al. Comparative and costeffectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among us elderly stage iv colon cancer patients. Cancer. 2012; 118: 3173-3181.
35. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebocontrolled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014; 32: 997-1005.
36. Di Bartolomeo M, Ciarlo A, Bertolini A, et al. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. Eur J Cancer. 2015; 51: 473-481.
37. O?Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014; 32: 1927-1934.
38. Jackson CG, Sharples K, Thompson PI, et al. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer. 2014; 14: 737.
39. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008; 100: 630-641.
40. Yabroff KR, Mariotto AB, Feuer E, et al. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ. 2008; 17: 947-959.
41. Bach PB. Limits on Medicare?s ability to control rising spending on cancer drugs. N Engl J Med. 2009; 360: 626-633.
42. Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012; 30: 1715-1724.
43. Schipper LE, Davidson NE, Wellins DS, et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015; 33: 2563-2578.
44. Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomized controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol. 2012; 23: 1531-1536.
45. McCleary NJ, Odejide O, Szymonifka J, et al. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer. 2013; 12: 62-69.
46. Jehn CF, Boning L, Kroning H, et al. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. Eur J Cancer. 2014; 50: 1269-1275.
47. Lund JL, Stu?rmer T, Harlan LC, et al. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care. 2013; 51: e27-e34.
48. American Cancer Society. Cancer facts & figures 2013. Available at: http: //www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures 2013/index. 2013. Accessed January. 25, 2016.
49. Ramsey S, Blough D, Kirchoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff. 2013; 32: 1143-1152.